Hepatitis C Treatment Market, 2012-2023

January 2018 | 193 pages | ID: H6E3D478952EN
Precision Business Insights (PBI)

Abstracts

Global Hepatitis C Treatment Market Outline: Hepatitis C Treatment Market

The global market for Hepatitis C treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis C infection. Rising awareness regarding Hepatitis C treatment, increase in healthcare expenditure, and government initiatives and various NGO’s creating awareness regarding the Hepatitis C treatment is expected to fuel the market growth over the forecast period. In addition, rise in the funding in research and development activities for Hepatitis C treatment and strong pipeline products might boost the global Hepatitis C treatment market over the forecast period. However, lack of antibiotics in the market, high cost of medications, and lack of hepatitis C infection awareness in poor countries might hamper the growth of global Hepatitis C treatment market over the forecast period.

Hepatitis C treatment market segmented on the basis of drug class, route of administration, and distribution channel

Based on drug class, the hepatitis C treatment market has been segmented into the following:

• Polymerase Inhibitors
• NS5A Inhibitors
• Interferons
• HCV protease inhibitors
• Combination Therapy

Based on route of administration, the hepatitis C treatment market has been segmented into the following:

• Oral
• Parenteral

Based on distribution channel, the hepatitis C treatment market has been segmented into the following:

• Retail Pharmacies
• Hospital Pharmacies
• Others

Increase in prevalence of hepatitis C infection and liver cirrhosis expected to fuel the growth of Hepatitis C treatment market. According to the World Health Organization (WHO), globally there are 80 Mn people suffers from chronic hepatitis C virus, in that approximately 700,000 will die each year as a result of the infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their market share in global hepatitis C treatment market. For instance, in July 2011, Merck MSD, inked an agreement with Roche for the marketing approvals of Victreli (Boceprevir) triple combination therapy with peginterferon alfa and ribavirin (peg/riba). In addition, in August 2011, Vertex Pharmaceuticals Incorporated announced that Health Canada approved its Incivektm (Telaprevir) tablets for people with genotype 1 chronic hepatitis C with compensated liver disease. In January 2014, European Commission (EC) granted marketing authorization for Gilead’s Sovaldi (Sofosbuvir) to treat chronic hepatitis C infection.

Geographically, the hepatitis C treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global hepatitis C treatment market followed by Europe and Asia-Pacific. Increase in prevalence of hepatitis C infection (according to Centres for Disease Prevention and Control (CDC), approximately 2.7-3.9 Mn people in the United States are chronically infected with hepatitis C Virus), rise in the awareness among the key stakeholders towards the use of novel products and technologies to treat the hepatitis C, and increase in research and development activities are the key factors bolster the hepatitis C treatment market in North America region. Europe holds a key share in hepatitis C treatment market owing to increase in prevalence of Hepatitis C infection (according to European centre for Disease Prevention and Control approximately 5.9 Mn people are suffering from HCV infection), rise in the geriatric population, change in the lifestyle, people involving in the unprotected sexual intercourse, and increase in the research and development activities might boost the hepatitis C treatment market in Europe region. Asia-Pacific hepatitis C treatment market growth is attributed to increase in the prevalence of hepatitis C infection, rise in the population in Asia-Pacific region, and increase in the healthcare infrastructure. The Middle East & Africa region has high prevalence of HCV infection majorly in Egypt that is approximately 8434 prevalent cases per 100,000 people.

Some of the players in Hepatitis C treatment market are GlaxoSmithKline, plc. (U.K.), Bristol-Myers Squibb (U.S), F. Hoffmann- La Roche Ltd. (Switzerland), Merck & Co, Inc. (U.S), Johnson & Johnson Services, Inc. (U.S.), Gilead Sciences (U.S.), AbbVie Inc. (U.S.), Vertex Pharmaceuticals Inc. (U.S.), and Kadmon Holdings, Inc. (U.S.) to name a few.

In August 2017, AbbVie received FDA approval for Mavyret (glecaprevir/pibrentasvir), for the chronic hepatitis C virus (HCV) infection in all major genotypes (GT1-6)

In July 2017, Gilead Sciences, Inc. received U.S. FDA approval for Vosevi used in re-treatment of the chronic hepatitis C virus (HCV) infection

In May 2015, Bristol-Myers Squibb received U.S. FDA breakthrough therapy designation for investigational drug Daclatasvir-based hepatitis C regimen

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL HEPATITIS C TREATMENT MARKET INTRODUCTION

2.1. Global Hepatitis C Treatment Market – Taxonomy
2.2. Global Hepatitis C Treatment Market –Definitions
  2.2.1. Drug Class
  2.2.2. Route of Administration
  2.2.3. Distribution Channel

3. GLOBAL HEPATITIS C TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hepatitis C Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Hepatitis C Treatment Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe
  3.6.3. Japan

4. GLOBAL HEPATITIS C TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL HEPATITIS C MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Polymerase Inhibitors
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. NS5A Inhibitors
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Interferons
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. HCV protease inhibitors
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Combination Therapy
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis

6. GLOBAL HEPATITIS C TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oral
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Parenteral
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis

7. GLOBAL HEPATITIS C TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Retail Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Others
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL HEPATITIS C TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Hepatitis C Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA HEPATITIS C TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Polymerase Inhibitors
  9.1.2. NS5A Inhibitors
  9.1.3. Interferons
  9.1.4. HCV protease inhibitors
  9.1.5. Combination Therapy
9.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Oral
  9.2.2. Parenteral
9.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Retail Pharmacies
  9.3.2. Hospital Pharmacies
  9.3.3. Others
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Hepatitis C Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
9.6. North America Hepatitis C Treatment Market Dynamics – Trends

10. EUROPE HEPATITIS C TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Polymerase Inhibitors
  10.1.2. NS5A Inhibitors
  10.1.3. Interferons
  10.1.4. HCV protease inhibitors
  10.1.5. Combination Therapy
10.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Oral
  10.2.2. Parenteral
10.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Retail Pharmacies
  10.3.2. Hospital Pharmacies
  10.3.3. Others
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Hepatitis C Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.6. Europe Hepatitis C Treatment Market Dynamics – Trends

11. ASIA-PACIFIC HEPATITIS C TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Polymerase Inhibitors
  11.1.2. NS5A Inhibitors
  11.1.3. Interferons
  11.1.4. HCV protease inhibitors
  11.1.5. Combination Therapy
11.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Oral
  11.2.2. Parenteral
11.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Retail Pharmacies
  11.3.2. Hospital Pharmacies
  11.3.3. Others
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Hepatitis C Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.6. Asia-Pacific Hepatitis C Treatment Market Dynamics – Trends

12. LATIN AMERICA HEPATITIS C TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Polymerase Inhibitors
  12.1.2. NS5A Inhibitors
  12.1.3. Interferons
  12.1.4. HCV protease inhibitors
  12.1.5. Combination Therapy
12.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Oral
  12.2.2. Parenteral
12.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Retail Pharmacies
  12.3.2. Hospital Pharmacies
  12.3.3. Others
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Hepatitis C Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Hepatitis C Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA HEPATITIS C TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Polymerase Inhibitors
  13.1.2. NS5A Inhibitors
  13.1.3. Interferons
  13.1.4. HCV protease inhibitors
  13.1.5. Combination Therapy
13.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Oral
  13.2.2. Parenteral
13.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Retail Pharmacies
  13.3.2. Hospital Pharmacies
  13.3.3. Others
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.4.1. Gulf Cooperation Council (GCC) Countries
  13.4.2. Israel
  13.4.3. South Africa
  13.4.4. Rest of MEA
13.5. MEA Hepatitis C Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.6. MEA Hepatitis C Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. GlaxoSmithKline, plc. (U.K.)
  14.2.2. Bristol-Myers Squibb (U.S)
  14.2.3. F. Hoffmann- La Roche Ltd. (Switzerland)
  14.2.4. Merck & Co, Inc. (U.S)
  14.2.5. Johnson & Johnson Services, Inc. (U.S.)
  14.2.6. Gilead Sciences (U.S.)
  14.2.7. AbbVie Inc. (U.S.)
  14.2.8. Vertex Pharmaceuticals Inc. (U.S.)
  14.2.9. Kadmon Holdings, Inc. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS